Arbutus Biopharma ABUS
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 90th percentile, 5-year average -6.6x
#153 of 2991 stocks by PE (1 = cheapest)
Near the top of its 5-year range · 80th percentile, 5-year average 3.9x
#4748 of 5329 stocks by PB (1 = cheapest)
Near the bottom of its 5-year range · 0th percentile, 5-year average 40.0x
#3409 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 7.32 | – | 3.91 | 80% (pricier than usual) | #4748 of 5329 (1 = cheapest) |
| PE | 3.65 | -38.40 | -6.63 | 90% (pricier than usual) | #153 of 2991 (1 = cheapest) |
| PS | 3.45 | 161.25 | 40.05 | 0% (cheaper than usual) | #3409 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on ABUS.
Sign in to join the discussion.